ardiovascular disease is significantly increased in patients with the metabolic syndrome and type 2 diabetes. A clustering of risk factors, including dyslipidaemia, insulin resistance, hypertension, inflammation and coagulation disorders are acting in concert to promote cardiovascular events in these patients. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that influence vascular function by altering gene expression in vascular tissue and indirectly via effects on other tissues. Indeed, PPAR activation displays beneficial effects on glucose homeostasis and lipid metabolism, and also on endothelial function and vessel wall inflammation. Clinically used PPARα agonists, such as fibrates, and PPARγ agonists, such as insulin-sensitising thiazolidinediones, may consequently alter the process of atherosclerosis, especially in subjects with the metabolic syndrome and type 2 diabetes. The present review highlights emerging evidence for beneficial effects of PPAR α and PPARγ in the prevention and treatment of atherosclerosis in such high-risk patients.
Staels B., Koenig W., Habib A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature1998;393:790-3.
8.
Neve BP, Corseaux D., Chinetti G. et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation2001 ;103:207-12.
9.
Marx N., Kehrle B., Kohlhammer K. et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis . Circ Res2002;90:703-10.
10.
Chinetti G. , Gbaguidi FG, Griglio S. et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation2000;101:2411-17.
11.
Chinetti G. , Fruchart JC, Staels B.Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol2003;14:459-68.
12.
Marx N., Duez H., Fruchart JC, Staels B.Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res2004;94:1168-78.
13.
Murao K., Imachi H., Momoi A. et al. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett1999;454:27-30.
14.
Jones DC, Ding X., Daynes RANuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem2002;277:6838-45.
15.
Wang P., Anderson PO, Chen S., Paulsson KM, Sjogren HO, Li S.Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol2001;1:803-12.
16.
Pasceri V., Wu HD, Willerson JT, Yeh ETModulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation2000 ;101:235-8.
17.
Goya K., Sumitani S., Xu X. et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol2004;24:658-63.
18.
Calnek DS, Mazzella L., Roser S., Roman J., Hart CMPeroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol2003;23:52-7.
19.
Delerive P. , Martin-Nizard F., Chinetti G. et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway . Circ Res2003;85:394-402.
20.
Xin X., Yang S., Kowalski J., Gerritsen MEPeroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem1999;274:9116-21.
21.
Chinetti G. , Lestavel S., Bocher V. et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med2001;7:53-8.
22.
Moore KJ, Rosen ED, Fitzgerald ML et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med2001;7:41-7.
23.
Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans RMPPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med2001;7:48-52.
24.
Liang CP, Han S., Okamoto H. et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest2004;113: 764-73.
25.
Akiyama TE, Sakai S., Lambert G. et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol2002;22:2607-19.
26.
Ricote M., Huang JT, Welch JS, Glass CKThe peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol1999;66:733-9.
27.
Shu H., Wong B., Zhou G. et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun2000;267:345-9.
28.
Marx N., Mackman N., Schonbeck U. et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation2001;103:213-19.
29.
Hourton D., Delerive P., Stankova J., Staels B., Chapman MJ, Ninio E.Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages. Biochem J2001;354:225-32.
30.
Ikeda Y., Sugawara A., Taniyama Y. et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J Biol Chem2000;275:33142-50.
31.
Durrington PN, Mackness MI, Bhatnagar D. et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia . Atherosclerosis1998;138:217-25.
32.
Kruszynska YT, Yu JG, Olefsky JM, Sobel BEEffects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes2000;49:633-9.
33.
Wakino S., Kintscher U., Kim S., Yin F., Hsueh WA, Law REPeroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells . J Biol Chem2000;275:22435-41.
34.
Law RE, Meehan WP, Xi XP et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest1996;98:1897-905.
35.
Gizard F., Amant C., Barbier O. et al. PPARa inhibits vascular smooth muscle cell proliferation through Trans-Activation of the gene Tumor suppressor p16Ink4a. Circulation2004;110(suppl):1326.
36.
Petrie JR, Ueda S., Webb DJ, Elliott HL, Connell JMEndothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation1996;93: 1331-3.
37.
Montagnani M., Golovchenko I., Kim I. et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem2002;277:1794-9.
38.
Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation2001;104:342-5.
39.
Vicent D., Ilany J., Kondo T. et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest2003;111:1373-80.
40.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
41.
The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977-86.
42.
Charbonnel B. , Dormandy J., Erdmann E., Massi-Benedetti M., Skene A.The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care2004;27:1647-53.
43.
Cruickshank K. , Riste L., Anderson SG, Wright JS, Dunn G., Gosling RGAortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?Circulation2002;106:2085-90.
44.
Satoh N., Ogawa Y., Usui T. et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care2003;26:2493-9.
45.
Pistrosch F. , Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P.In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care2004;27:484-90.
46.
Wang TD, Chen WJ, Lin JW, Chen MF, Lee YTEffects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol2004;93:362-5.
47.
Caballero AE , Saouaf R., Lim SC et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism2003 ;52:173-80.
48.
Koshiyama H. , Shimono D., Kuwamura N., Minamikawa J., Nakamura Y.Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab2001;86: 3452-6.
49.
Takagi T., Yamamuro A., Tamita K. et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J2003 ;146:E5.
50.
Choi D., Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care2004;27:2654-60.
51.
Osman A., Otero J., Brizolara A. et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J2004;147:e23.
52.
Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med2000;342:836-43.
53.
Haffner SM, Greenberg AS, Weston WM, Chen H., Williams K., Freed MIEffect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation2002;106:679-84.
54.
Marx N., Froehlich J., Siam L. et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol2003;23:283-8.
55.
Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients . Diabetes Care2002;25:376-80.
56.
Fullert S., Schneider F., Haak E. et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab2002;87:5503-06.
57.
Raji A., Seely EW, Bekins SA, Williams GH, Simonson DCRosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care2003;26:172-8.
58.
Shargorodsky M., Wainstein J., Gavish D. et al. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens2003;16:617-22.
59.
Khan MA, St Peter JV, Xue JLA prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care2002;25:708-11.
60.
van Wijk JP , de Koning EJ, Martens EP, Rabelink TJThiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol2003; 23:1744-9.
61.
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905-10.
62.
Ericsson CG , Hamsten A., Nilsson J., Grip L., Svane B., de Faire, U.Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients . Lancet1996;347:849-53.
63.
Frick MH, Syvanne M., Nieminen MS et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. Circulation1997;96:2137-43.
64.
Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med1999;341:410-18.
65.
Frick MH, Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987;317:1237-45.
66.
Elkeles RS, Diamond JR, Poulter C. et al. Cardiovascular outcomes in type 2 diabetes.A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care1998;21:641-8.
67.
Evans M., Anderson RA, Graham J. et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation2000;101:1773-9.
68.
van Venrooij F., van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JDAggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care2002;25:1211-16.
69.
Sheu WH, Juang BL, Chen YT, Lee WJEndothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care1999;22:1224-5.
70.
Sheu WH, Chen YT, Lee WJImprovement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients. Diabetes Care2001;24:1499-501.
71.
Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam, KSAtorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab2002;87:563-8.
72.
Pasceri V., Cheng JS, Willerson JT, Yeh ET, Chang J.Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation2001; 103:2531-4.
73.
Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S.Glitazones and heart failure: critical appraisal for the clinician. Circulation2003;107:1350-4.
74.
Shiomi T., Tsutsui H., Hayashidani S. et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation2002;106:3126-32.
75.
Fonarow GCApproach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J2004;148:551-8.
76.
Nesto RW, Bell D., Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care2004;27:256-63.
77.
Olefsky JMTreatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest2000;106:467-72.
78.
Rocchi S., Picard F., Vamecq J. et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell2001; 8:737-47.
79.
Sauerberg P. , Pettersson I., Jeppesen L. et al. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity . J Med Chem2002;45:789-804.
80.
Duran-Sandoval D., Thomas AC, Bailleul B., Fruchart JC, Staels B.[Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]. Med Sci (Paris) 2003;19:819-25.
